The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (OGSG 1106).
 
Hiroki Yukami
No Relationships to Disclose
 
Masahiro Goto
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Taiho Pharmaceutical
 
Takayuki Kii
No Relationships to Disclose
 
Tetsuji Terazawa
No Relationships to Disclose
 
Toshifumi Yamaguchi
No Relationships to Disclose
 
Fukutaro Shimamoto
No Relationships to Disclose
 
Hitoshi Nishitani
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Toshio Shimokawa
No Relationships to Disclose
 
Yoshihiro Matsubara
No Relationships to Disclose
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yukinori Kurokawa
Honoraria - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Medtronic; MSD; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Yakult Honsha
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Ono Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)